Flagship-backed Foghorn woos Bristol-Myers vet Carl Decicco to direct its 'gene traffic control' platform
A number of years ago, Carl Decicco happened to catch a presentation by a young Dana-Farber researcher named Cigall Kadoch. She was talking about the BAF chromatin remodeling complex and the importance of it in medicine.
“I remember thinking that if she’d ever be able to accomplish what she was proposing, it would be quite an area to be a part of,” he says.
That became reality this week as Decicco leaves a decades-long career at Bristol-Myers Squibb to become chief scientific officer #1 and employee #51 at Foghorn Therapeutics, a biotech co-founded by Kadoch to focus on the chromatin regulatory system.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
